RMC-9805-001

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 15, 2023 → Sep 26, 2026

Cited window

Sep 15, 2023 → Jul 6, 2026

Retrieved

Oct 29, 2026

Title

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Registry

NCT06040541

Study IDs

RMC-9805-001

Sponsor

Revolution Medicines, Inc.

Design

Phase 1 · Interventional, non randomized, parallel

Status

Recruiting

Enrollment

604 estimated

Registered

2023-09-15

Start

2023-09-07 actual

Primary completion

2026-12-31 estimated

Primary endpoint

Adverse events

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on mutation-defined eligibility for investigational combination treatments in non-small cell lung cancer.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some passages were not fully assessed, and many potentially relevant sources without an explicit trial name were not read.
• –Unnamed references and transcription variants may be missing. One potentially relevant statement could not be used because its molecular-eligibility wording was unreliable.
• –Clinical roles are not established for several named social-media authors. Source descriptions such as MD or PhD are not independent verification of a clinical role, and an organizational relay is not necessarily its author's own clinical view.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Repeated posts, reposts and multiple unidentified turns do not establish independent HCP agreement or consensus.
• –Comments on early RMC-9805 work or the same treatment setting that do not name the trial are attributed context, not additional identified results from NCT06040541. A general PDAC video's genomic-profiling recommendation is selection context, not G12D efficacy evidence.
• –Early-phase, selected-population and cross-study observations do not establish superiority over chemotherapy, docetaxel or a single RAS inhibitor. Predictions and conditional efficacy thresholds remain predictions and conditions.
• –No protocol, matching regulatory label or trial results publication is included. Statements about FDA designation and dose-selection consultation remain attributed presentation remarks.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "RMC-9805-001" (NCT06040541), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rmc-9805-001-06040541". If you cannot make requests, read https://www.erudio.com/reports/rmc-9805-001-nct06040541.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06040541", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06040541 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/rmc-9805-001-nct06040541.json
curl https://www.erudio.com/reports/rmc-9805-001-nct06040541.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rmc-9805-001-06040541" })